New approaches to prevent intestinal toxicity of irinotecan-based regimens.
about
Chemotherapy induced diarrhea.Contributions made by CDC25 phosphatases to proliferation of intestinal epithelial stem and progenitor cellsDevelopment of the rat model of lapatinib-induced diarrhoea.Antitumor effect of D-erythrose in an abdominal metastatic model of colon carcinoma.Understanding and modulating mammalian-microbial communication for improved human health.Local bacteria affect the efficacy of chemotherapeutic drugs.Dark Agouti rat model of chemotherapy-induced mucositis: establishment and current state of the art.Capecitabine in combination with irinotecan (XELIRI), administered as a 2-weekly schedule, as first-line chemotherapy for patients with metastatic colorectal cancer: a phase II study of the Spanish GOTI group.Chimonanthus nitens var. salicifolius Aqueous Extract Protects against 5-Fluorouracil Induced Gastrointestinal Mucositis in a Mouse ModelPharmacokinetics and safety of DTS-108, a human oligopeptide bound to SN-38 with an esterase-sensitive cross-linker in patients with advanced malignancies: a Phase I study.Phase I/II study of sequential therapy with irinotecan and S-1 for metastatic colorectal cancerHepatic portal venous gas: physiopathology, etiology, prognosis and treatment.Therapeutic targeting of CPT-11 induced diarrhea: a case for prophylaxis.Glucuronides from metabolites to medicines: a survey of the in vivo generation, chemical synthesis and properties of glucuronides.Rapid deconjugation of SN-38 glucuronide and adsorption of released free SN-38 by intestinal microorganisms in rat.Irinotecan side effects relieved by the use of HI-6 oxime: in vivo experimental approach.Crypt Organoid Culture as an in Vitro Model in Drug Metabolism and Cytotoxicity Studies.Concomitant administration of bevacizumab, irinotecan, 5-fluorouracil, and leucovorin: nonclinical safety and pharmacokinetics.Shengjiang Xiexin Decoction Alters Pharmacokinetics of Irinotecan by Regulating Metabolic Enzymes and Transporters: A Multi-Target Therapy for Alleviating the Gastrointestinal Toxicity.Kampo medicine "Dai-kenchu-to" prevents CPT-11-induced small-intestinal injury in rats.Effect of hesperidin on the pharmacokinetics of CPT-11 and its active metabolite SN-38 by regulating hepatic Mrp2 in rats.
P2860
Q33307663-9772EA00-828B-4521-9841-55C9CF1DD624Q33808811-15938979-E1F7-43BA-B975-FE13B010B2F1Q33999288-9E59972C-C201-49EB-A7B3-FFCEE1C53B74Q34993787-A2A8ECE6-7BF4-4325-80A2-083975D2037BQ35026463-D25FF8DB-2D19-477F-A227-B8DDDE404ADAQ36102269-9B03A04B-2D2C-4C60-A680-68BED9A590CBQ37071033-2473C032-22F3-4CC7-A145-E62F5B16F64BQ37400585-D4005A51-53FB-4491-9E7C-1F84D75E30D3Q37400586-561D58CD-D96B-4027-87A5-290B5FFB6202Q37441604-B0A615D3-3371-45A9-BB68-789121305F79Q37481906-4DB92AAC-5C32-4624-A470-1AD33AB29B4FQ37571720-15B84534-2274-467D-8ADC-742C50F1C25AQ37731433-31A06F13-1517-477F-A529-AB9E10595ED6Q38104574-B37AF914-8AAE-45BE-A98D-23CCEC5DE57CQ42180635-5FE6078B-D293-43EC-B227-0A975CCBFF2CQ43296405-E14B1A48-15F7-4BED-B354-521E90BAA3FEQ46523099-E230658B-7DBB-49A9-AEA8-C33C4ACAB03EQ46781537-1EEDB06E-F764-41EF-B789-50264C70719BQ47107453-D303E62D-90AF-461F-B358-2A3C9A681218Q47251445-66EC4C06-9DFD-4D6F-8E4A-5EDE6419F2A5Q51579192-0B56F9D4-7599-4A6C-BA88-2C4E4A7ABC8B
P2860
New approaches to prevent intestinal toxicity of irinotecan-based regimens.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
New approaches to prevent intestinal toxicity of irinotecan-based regimens.
@ast
New approaches to prevent intestinal toxicity of irinotecan-based regimens.
@en
type
label
New approaches to prevent intestinal toxicity of irinotecan-based regimens.
@ast
New approaches to prevent intestinal toxicity of irinotecan-based regimens.
@en
prefLabel
New approaches to prevent intestinal toxicity of irinotecan-based regimens.
@ast
New approaches to prevent intestinal toxicity of irinotecan-based regimens.
@en
P2093
P1476
New approaches to prevent intestinal toxicity of irinotecan-based regimens.
@en
P2093
Alain Gelibter
Aldo Vecchione
Andrea Alimonti
Debora Rasio
Francesco Cognetti
Francesco Satta
Gianluigi Ferretti
Ida Pavese
Mario Di Palma
P304
P356
10.1016/J.CTRV.2004.05.002
P577
2004-10-01T00:00:00Z